Omnitrope (somatropin [rDNA origin]), is a recombinant human growth hormone product. It is approved by the FDA for use in children and adults for the treatment of clinical human growth hormone deficiency. Omnitrope produces the same benefits as other forms of HGH, but differs in its inactive ingredients, as well as the products available to improve and simplify the injection process.
What is Omnitrope used for?
Omnitrope is indicated for long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone, and for long-term replacement therapy in adults with GHD of either childhood- or adult onset. Growth hormone deficiency is a significant medical condition that impacts patients of all ages and both genders. In children, HGH deficiency inhibits growth, and in adults, growth hormone deficiency impairs health and well-being in a chronic way.
Pediatric GHD Patients
Generally, a dose of 0.16 to 0.24 mg/kg body weight/week is recommended. In the majority of patients, this range of dosage encourages growth patterns nearly identical to those of patients with healthy functioning pituitary glands.
Adult GHD Patients
After puberty has completed and a person reaches his or her final adult height, human growth hormone levels drop to a lower point, not to encourage growth, but to sustain the cellular metabolism necessary to keep the body functioning optimally. The recommended dosage at the start of therapy is not more than 0.04 mg/kg/week. Some patients respond readily to this lower dosage, while others need to have their dosage increased. The dose may be increased at 4- to 8-week intervals according to individual patient requirements to a maximum of 0.08 mg/kg/week, depending upon patient tolerance of treatment. Clinical response, side effects, and determination of age-adjusted serum IGF-I may be used as guidance in dose titration. This approach will tend to result in weight-adjusted doses that are larger for women compared with men and smaller for older and obese patients. Omnitrope is available in vials and 2 different pen type delivery devices, the Pen 5 and Pen 10, offering minimum doses of .05mg and .1mg respectively. Omnitrope pens provide a safe and easy way to deliver HGH injections nearly painlessly.
Founded in 1886 Sandoz has a long history of being a leader in the pharmaceutical industry. Sandoz is focused on both researching new drugs and bringing them to market as well as manufacturing generic drugs and making them affordable as possible in an effort to spread their benefit to people around the world. Sandoz is a subsidiary of Novartis and did over $10 billion dollars in revenue in 2011. They are headquartered in Holzkirchen, Germany.